| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Tyrphostin AG 825 targets ErbB2 (HER2). It is a selective, ATP-competitive inhibitor that binds to the ATP-binding site of the ErbB2 kinase domain, preventing its autophosphorylation and activation. This inhibition blocks downstream signaling pathways that promote cell proliferation and survival. The compound shows high selectivity for ErbB2 over ErbB1.
|
|---|---|
| ln Vitro |
In vitro, tyrphostin AG 825 has been shown to be a potent inhibitor of ErbB2 tyrosine phosphorylation. It induces apoptosis in androgen-independent prostate cancer cells. The compound's activity is characterized by its low IC50 for ErbB2. It has also been shown to accelerate the apoptosis of human neutrophils.
|
| ln Vivo |
In vivo, tyrphostin AG 825 has been studied for its anti-cancer activity in animal models. Its ability to induce apoptosis in cancer cells makes it a potential candidate for the treatment of cancers that overexpress ErbB2.
|
| Enzyme Assay |
In vitro enzyme or receptor binding (non-cell) assays for tyrphostin AG 825 involve measuring its direct inhibition of ErbB2 kinase activity. The assay uses a purified recombinant ErbB2 kinase enzyme and a peptide substrate in the presence of ATP. The phosphorylation of the substrate is measured using a radioactive or fluorescent method. The compound is incubated with the enzyme and substrate, and the decrease in phosphorylation is measured to determine the IC50.
|
| Cell Assay |
In vitro cell-based assays for tyrphostin AG 825 are performed using cancer cell lines that overexpress ErbB2, such as BT-474 or SK-BR-3 cells. Cells are treated with the compound, and cell viability and apoptosis are assessed using standard assays. The compound's effects on ErbB2 phosphorylation and downstream signaling pathways are analyzed by Western blotting.
|
| Animal Protocol |
In vivo animal experiments for tyrphostin AG 825 are conducted using mouse xenograft models of cancer. Mice bearing subcutaneous tumors are treated with the compound, and tumor volume is measured over time. The compound's effects on tumor growth and survival are evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of tyrphostin AG 825 have been characterized to support its use as a research tool. The compound has a molecular weight of 397.47 and a formula of C₁₉H₁₅N₃O₃S₂. It is soluble in DMSO. Specific PK parameters, such as half-life and bioavailability, are determined in preclinical studies via LC-MS/MS analysis of plasma samples.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for tyrphostin AG 825 are typical of a research compound. It is generally well-tolerated at effective doses. The safety profile is being evaluated in the context of its use as a research tool to study ErbB2 signaling.
|
| References |
|
| Additional Infomation |
Tyrphostin AG 825 is an organosulfur compound composed of 1,3-benzothiazol-2-thiol, in which the hydrogen atom bonded to the sulfur atom is replaced by 5-[(1E)-3-amino-2-cyano-3-oxoprop-1-en-1-yl]-2-hydroxy-3-methoxybenzyl. It is an epidermal growth factor receptor antagonist. It is an enamide, nitrile, phenolic compound, aromatic ether, benzothiazolium compound, organosulfur compound, and primary amide. Functionally, it is associated with 1,3-benzothiazol-2-thiol. Tyrphostin AG 825 is a member of the tyrphostin family of tyrosine kinase inhibitors and selectively inhibits HER2. (NCI)
Other information: Tyrphostin AG 825 is a research compound used to study the role of ErbB2 in cancer. It is available from chemical suppliers for preclinical research purposes. |
| Molecular Formula |
C19H15N3O3S2
|
|---|---|
| Molecular Weight |
397.467
|
| Exact Mass |
397.055
|
| CAS # |
149092-50-2
|
| PubChem CID |
6091659
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
689.3±65.0 °C at 760 mmHg
|
| Flash Point |
370.7±34.3 °C
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
| Index of Refraction |
1.733
|
| LogP |
2.89
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
621
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC(=CC(=C1O)CSC2=NC3=CC=CC=C3S2)/C=C(\C#N)/C(=O)N
|
| InChi Key |
KXDONFLNGBQLTN-WUXMJOGZSA-N
|
| InChi Code |
InChI=1S/C19H15N3O3S2/c1-25-15-8-11(6-12(9-20)18(21)24)7-13(17(15)23)10-26-19-22-14-4-2-3-5-16(14)27-19/h2-8,23H,10H2,1H3,(H2,21,24)/b12-6+
|
| Chemical Name |
(E)-3-[3-(1,3-benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-methoxyphenyl]-2-cyanoprop-2-enamide
|
| Synonyms |
Tyrphostin AG825 Tyrphostin AG-825 Tyrphostin AG 825
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~628.98 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.23 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5159 mL | 12.5796 mL | 25.1591 mL | |
| 5 mM | 0.5032 mL | 2.5159 mL | 5.0318 mL | |
| 10 mM | 0.2516 mL | 1.2580 mL | 2.5159 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
